Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?
The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...
STAT11d
Pharma’s ethically questionable sites essentially sell drugs directly to consumers
Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...
BioSpace2d
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...
FiercePharma4d
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...
U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...
Pharma stocks sink on RFK Jr. pick
Welcome to The Hill’s Business & Economy newsletter{beacon} Business & Economy Business & Economy   The Big Story Pharma stocks sink after RFK Jr. tapped to lead ...